Equity Details
Price & Market Data
Price: $5.23
Daily Change: +$0.065 / 1.24%
Daily Range: $5.09 - $5.34
Market Cap: $16,760,812
Daily Volume: 22,150
Performance Metrics
1 Week: 2.40%
1 Month: -12.68%
3 Months: -43.84%
6 Months: -26.82%
1 Year: -16.38%
YTD: -54.79%
About Passage Bio, Inc. (PASG)
Get immediate market data for Passage Bio, Inc. (PASG). Price: 5.23, daily change: +$0.065 / 1.24%. Market cap: 16,760,812. All performance metrics at your fingertips.
Company Details
Employees: 24
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other programs for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is based in Philadelphia, Pennsylvania.
